Aurinia Pharmaceuticals (AUPH) Non-Current Assets (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Non-Current Assets came in at $243.8 million in Q1 2026, up 146.0% YoY from $99.1 million in Q1 2025, and down 6.11% on a QoQ basis from $259.6 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Non-Current Assets (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 11 years of Non-Current Assets data on file, last reported at $243.8 million in Q1 2026.
- Quarterly Non-Current Assets rose 146.0% year-over-year to $243.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $685.8 million (up 61.01% YoY) and the FY2025 annual result came in at $259.6 million, up 149.52% from the prior year.
- Non-Current Assets slipped to $243.8 million in Q1 2026, from $259.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $259.6 million in Q4 2025 to a low of $28.1 million in Q1 2023.
- A 5-year average of $103.4 million and a median of $104.0 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 34.68% — and 2023, when it jumped 359.31%.
- Tracing AUPH's Non-Current Assets over 5 years: stood at $28.3 million in 2022, then jumped by 335.23% to $123.3 million in 2023, then declined by 15.59% to $104.0 million in 2024, then jumped by 149.52% to $259.6 million in 2025, then decreased by 6.11% to $243.8 million in 2026.
- The last three Non-Current Assets figures came in at $243.8 million (Q1 2026), $259.6 million (Q4 2025), and $88.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 250.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 250.94 Mn |
| Mar 31, 2026 | 243.75 Mn |
| Dec 31, 2025 | 259.62 Mn |
| Sep 30, 2025 | 88.79 Mn |
| Jun 30, 2025 | 93.59 Mn |
| Mar 31, 2025 | 99.09 Mn |
| Dec 31, 2024 | 104.05 Mn |
| Sep 30, 2024 | 108.90 Mn |
| Jun 30, 2024 | 113.86 Mn |
| Mar 31, 2024 | 118.41 Mn |
| Dec 31, 2023 | 123.26 Mn |
| Sep 30, 2023 | 128.54 Mn |
| Jun 30, 2023 | 132.99 Mn |
| Mar 31, 2023 | 28.11 Mn |
| Dec 31, 2022 | 28.32 Mn |
| Sep 30, 2022 | 28.59 Mn |
| Jun 30, 2022 | 28.96 Mn |
| Mar 31, 2022 | 29.28 Mn |
| Dec 31, 2021 | 30.04 Mn |
| Sep 30, 2021 | 30.85 Mn |